A study at The University of Texas MD Anderson Cancer Center has identified miR-506, a non-coding “micro” RNA molecule, as a likely robust clinical marker for epithelial ovarian cancer chemotherapy, and as a potential therapy due to its ability to sensitize cancer cells to chemotherapy. Epithelial ovarian cancer accounts for approximately 90 percent of all ovarian cancers. Ovarian cancer is the leading cause of death from gynecologic cancers in the U.S.
Zhang’s study, which included data from The Cancer Genome Atlas and other independent clinical populations as well as study of mouse models, observed “statistically significant improved responses” to the chemotherapy drugs cisplatin and olaparib when miR-506 was added to the treatment. Standard treatments include surgery and platinum-based chemotherapy, and the five-year survival rates for patients with advanced ovarian cancer is 30 to 40 percent.
Chemoresistance is a major challenge in cancer treatment and this study may provide a means to overcome resistance, said Zhang. His team’s findings are published online in the July issue of the Journal of the National Cancer Institute.
“Our previous study found that miR-506 is a potent inhibitor of a process known as epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance,” he said. “This study provides further insight into this molecule’s role in augmenting chemotherapy responses by directly affecting the DNA repair process used by cancer cells to counter DNA damages caused by chemotherapy.”
Prior investigations by Zhang’s group observed that miR-506 suppressed cancer cell EMT. The current study showed that miR-506 also regulated RAD51, a protein involved in DNA repair that contributes to chemotherapy resistance when overexpressed.
MD Anderson study participants included Guoyan Liu, M.D., Ph.D., Da Yang, Ph.D., Yan Sun, M.D., Ph.D., Xia Li, Ph.D., David Cogdell, and Limei Hu, M.D., all of Pathology; Cristian Rodriguez-Aguayo, Ph.D. and Gabriel Lopez-Berestein, M.D., Experimental Therapeutics; Rajesha Rupaimoole, Ph.D., Lingegowda Mangala, Ph.D., and Anil Sood, M.D., Gynecologic Oncology and Reproductive Medicine; and Chad Pecot, M.D., Cancer Medicine. Other participating institutions included Tianjin Medical University, Tianjin, China; the Fourth Military Medical University, Xian, China; the Institute for Systems Biology, Seattle; and the Fondazione IRCCS Instituto Nazionale dei Tumori, Milan.
The study was funded by the National Institutes of Health (U24CA143835, P50 CA083639, P50 CA098258, U54CA151668, and CA016672), the Cancer Prevention Research Institute of Texas (RP110595), the Ovarian Cancer Research Fund Inc., the Blanton-Davis Ovarian Cancer Research Program, the Asian Foundation for Cancer Research, the Associazione Italiana per la Ricerca sul Cancro, the National Science Foundation of China (81101673, 81472761 and 81201651), the Tianjin Science and Technology Committee Foundation (14JCYBJC25300), PCSIRT, and the National Key Scientific and Technological Project.
The University of Texas MD Anderson Cancer Center